Veita Bland, MD
Family Medicine · Greensboro, NCNPI 1083675433
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,301 of the $51,303 with a category attached, or 70.8%. Janssen Scientific Affairs, LLC accounts for 66.3% of it on its own, with 53 other manufacturers making up the rest. Reporting peaked in 2022 at $17,201 and has fallen 84.5% since, to $2,672 in 2025. Among family medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 673 payments — averaging $76.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$34K
- Idorsia Pharmaceuticals US Inc$2K
- Amgen$2K
- AstraZeneca$2K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- Bayer$1K
- plus $9K from 48 others
Across 20 payments — averaging $2817.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$27K
- Sanofi US Services Inc.$20K
- Bayer$9K
What the payments were for
- Consulting fees$36,30171%
- Speaking & faculty fees$2,1004%
- Travel & lodging$2,0724%
- Food & beverage$10,62221%
- Education$2080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,303 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 142 | $230,239 |
| JardianceEmpagliflozin | 192 | $199,157 |
| FarxigaDapagliflozin Propanediol | 111 | $105,606 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 80 | $69,014 |
| JanuviaSitagliptin Phosphate | 58 | $56,951 |
| RybelsusSemaglutide | 29 | $53,438 |
| MounjaroTirzepatide | 27 | $44,118 |
| EntrestoSacubitril/Valsartan | 44 | $37,541 |
| GemtesaVibegron | 37 | $33,596 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $33,554 |
| XareltoRivaroxaban | 32 | $32,974 |
| TrulicityDulaglutide | 24 | $31,817 |
| KerendiaFinerenone | 21 | $22,377 |
| JanumetSitagliptin Phos/Metformin Hcl | 33 | $21,477 |
| LinzessLinaclotide | 31 | $19,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,096 | $287,885191 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Jentadueto, Tradjenta | $642 | $235,050249 claims |
| MerckJanumet Xr, Januvia, Janumet, Steglatro | $510 | $151,772183 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,609 | $143,246181 claims |
| Lilly USA, LLCMounjaro, Trulicity | $737 | $75,93551 claims |
| Johnson & JohnsonXarelto, Invokana | $155 | $47,22543 claims |
| NovartisEntresto | $353 | $37,54144 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $59 | $33,59637 claims |
| AbbVieLinzess, Namzaric, Synthroid | $543 | $33,17677 claims |
| BayerKerendia | $1,401 | $22,37721 claims |
| PfizerEliquis | $210 | $13,90318 claims |
| Esperion Therapeutics, Inc.Nexletol | $210 | $13,01822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Greensboro
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
- Christopher ChaoCary$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.